BEIJING, China, Nov. 25, 2025 — Innovent Biologics and Eli Lilly announced that the supplementary application for Mazdutide 9mg has been officially accepted for review by China’s National Medical Products Administration (NMPA), signaling a major regulatory milestone for what may become a novel therapeutic option for adults with moderate-to-severe obesity. Mazdutide, a next-generation GLP-1/glucagon receptor dual agonist, has shown substantial weight-loss efficacy in Phase 3 studies and represents a potentially transformative advance in metabolic disease treatment.
Science Significance
The scientific relevance of Mazdutide 9mg lies in its innovative dual-agonist mechanism targeting both the GLP-1 receptor and glucagon receptor, combining appetite suppression, improved glycemic control, and enhanced energy expenditure. In clinical studies, Mazdutide demonstrated robust weight reduction, significant metabolic improvements, and a favorable biochemical response profile across Chinese populations. Its differentiated pharmacology positions it as a next-generation metabolic therapy capable of addressing obesity’s multifactorial physiology. The 9mg dose showed enhanced efficacy compared with lower doses, offering a strong scientific rationale for expanding dose options in clinical practice.
Regulatory Significance
Acceptance of the Mazdutide 9mg application by the NMPA reflects the strength of the drug’s late-stage clinical data, marking a key step toward potential approval in one of the world’s largest obesity markets. The supplementary application follows rigorous evaluation under Good Clinical Practice (GCP) standards and positions Mazdutide for potential label expansion to cover moderate-to-severe obesity. As obesity treatments increasingly undergo heightened regulatory scrutiny due to long-term safety considerations, NMPA’s formal review underscores confidence in Mazdutide’s safety, tolerability, and clinical benefit profile, paving the way for regulatory pathways influencing future metabolic drug approvals in China.
Business Significance
Advertisement
For Innovent and Lilly, the advancement of Mazdutide 9mg strengthens their competitive position in the rapidly expanding global anti-obesity therapeutics market, now one of the highest-growth segments in biopharma. Successful approval would significantly enhance commercial differentiation and complement existing metabolic portfolios, providing a strategic foothold in Asia’s rising obesity-treatment landscape. With demand for effective obesity drugs surging across China, the 9mg formulation may capture considerable market share by offering a powerful therapeutic alternative aligned with patient needs and healthcare-system demands. The regulatory progress also reinforces Innovent’s domestic leadership and strategic partnership value.
Patients’ Significance
Obesity affects over 90 million adults in China, contributing to diabetes, cardiovascular disease, and reduced quality of life. Mazdutide’s clinical performance suggests meaningful improvements in weight management, metabolic function, and overall health outcomes for individuals facing moderate-to-severe obesity. A higher-dose formulation provides additional therapeutic flexibility, allowing physicians to optimize treatment for patients who require greater pharmacologic support. If approved, Mazdutide 9mg may offer a more accessible and effective option for individuals who have struggled with lifestyle modification alone or are seeking alternatives to bariatric surgery.
Policy Significance
The NMPA’s acceptance aligns with China’s broader public-health priorities aimed at combating the rising prevalence of obesity and metabolic disease. As policymakers increasingly emphasize preventive healthcare, chronic-disease management, and accessible therapeutic innovation, approval of advanced metabolic agents like Mazdutide can contribute to national health-strategy objectives. The progress of Mazdutide also reflects policy momentum toward supporting evidence-based metabolic therapies, expanding insurance coverage frameworks, and encouraging innovation in treatments addressing pressing public-health needs.
Mazdutide 9mg’s entry into NMPA review marks a significant regulatory and scientific milestone in China’s evolving obesity-care landscape. With compelling clinical data, a strong mechanistic foundation, and potential impact across patient populations, the therapy stands poised to become a valuable addition to modern obesity management. As Innovent and Lilly continue advancing metabolic-disease innovation, the acceptance of this supplementary application underscores growing momentum toward expanding therapeutic options and improving long-term health outcomes for individuals living with obesity.
Source: Innovent Biologics press release
